Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.58 |
| ▸ | CCR5 | P51681 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980152 | 0.82 | C5AR1 (0.62) | C5AR1OPRM1CCR5DRD2SIGMAR1 | |
| SCHEMBL3594347 | 0.81 | OPRM1 (0.58) | OPRM1CCR5DRD2SIGMAR1KMT2A | |
| SCHEMBL3586725 | 0.80 | DRD2 (0.58) | C5AR1DRD2SIGMAR1KCNA3KMT2A | |
| SCHEMBL3044722 | 0.79 | ALOX5 (0.60) | C5AR1OPRM1CCR5DRD2SIGMAR1 | |
| SCHEMBL8971246 | 0.78 | DRD2 (0.59) | C5AR1OPRM1DRD2SIGMAR1KCNA3 | |
| SCHEMBL3604725 | 0.78 | LTA4H (0.60) | C5AR1DRD2SIGMAR1KCNA3LTA4H | |
| SCHEMBL3598407 | 0.78 | OPRM1 (0.53) | OPRM1DRD2SIGMAR1 | |
| SCHEMBL5709503 | 0.77 | DRD2 (0.61) | C5AR1DRD2SIGMAR1KCNA3KMT2A | |
| SCHEMBL2980435 | 0.76 | KCNA3 (0.51) | C5AR1OPRM1DRD2SIGMAR1KCNA3 | |
| SCHEMBL3946392 | 0.76 | CHRM4 (0.62) | OPRM1DRD2SIGMAR1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | claimed |
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | C5AR1 1744/4885OPRM1 782/4885CCR5 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.